Royalty Pharma plc 8K

Royalty Pharma plc reported strong Q2 2026 results with double-digit Royalty Receipts growth, raised its 2026 Portfolio Receipts guidance, and continued significant capital deployment including acquisition of a major new royalty interest while highlighting numerous positive regulatory and clinical milestones across its portfolio.

On August 5, 2026, Royalty Pharma plc reported its second quarter 2026 financial results, highlighting 14% growth in Royalty Receipts to $768 million and 6% growth in Portfolio Receipts to $773 million, alongside net cash provided by operating activities of $728 million and non-GAAP Adjusted EBITDA and Portfolio Cash Flow of $736 million each. The company raised its full-year 2026 Portfolio Receipts guidance to a range of $3.4–$3.5 billion, implying expected Royalty Receipts growth of 7–10%, and reiterated expectations for operating and professional costs at 5.5–6.5% of Portfolio Receipts and interest paid of $350–$360 million, assuming no additional 2026 debt financings and reflecting repayment of a $380 million term loan in July 2026. Royalty Pharma also disclosed active capital deployment of $349 million in the quarter and $877 million year-to-date, including acquisition of a portion of Neurimmune AG’s royalty interest in AstraZeneca’s Phase 3 TTR amyloidosis antibody cliramitug for up to $425 million, and noted multiple positive regulatory and clinical developments across its royalty portfolio (e.g., FDA and EC approvals or filings for daraxonrasib, Jideytro, Trodelvy, Imdelltra, and others), supporting continued growth of its diversified biopharma royalty franchise.

Filing Facts

CIK

1802768

Ticker

RPRX

Form

8K

Source Type

fda

Accession

0001802768-26-000014

Alert Tier

7